Intermediatebiotechnology

Genetic Disorders Overview

Overview

Genetic disorders arise from DNA abnormalities: single-gene (Mendelian: CF, Huntington's, sickle cell), chromosomal (Down syndrome, Turner), and multifactorial (heart disease, diabetes: genes + environment). ~7,000 rare Mendelian disorders affect ~300 million people collectively; multifactorial diseases dominate mortality. Diagnosis, counseling, and emerging therapies (gene therapy, CRISPR) define modern management.

Learning objectives

  • Classify disorder types
  • Estimate burden and frequency
  • Explain diagnosis pathways
  • Survey treatment approaches

Single-gene disorders

~7,000 known; individually rare, collectively common (~1 in 17 people affected by a rare disease). Autosomal dominant (Huntington's), recessive (CF, Tay-Sachs), X-linked (hemophilia, DMD). Most are serious, early-onset, and lack cures: management is symptomatic plus surveillance.

Rare individually, common collectively

~300 million people worldwide live with a rare disease: not rare at all.

Chromosomal disorders

Aneuploidies (Down 1/700, Edwards, Patau), deletions/duplications (cri-du-chat, 22q11.2), sex chromosome (Turner, Klinefelter). Usually de novo (nondisjunction) with low recurrence; maternal age raises trisomy risk. Microarray is first-line diagnosis for developmental delay.

De novo dominates

Most chromosomal disorders are new mutations: parents' recurrence risk is low (~1%).

Multifactorial disorders

Heart disease, diabetes, schizophrenia, most cancers: many variants (polygenic risk) plus environment. Heritability is substantial but no single gene explains cases; GWAS/PRS stratify risk. Prevention targets modifiable factors; genetics guides screening intensity.

Common disease, many genes

No single 'diabetes gene': risk is distributed across thousands of variants.

Management and hope

Symptomatic care, surveillance protocols, genetic counseling, prenatal options; emerging: enzyme replacement, small molecules (CFTR modulators: Trikafta), gene therapy (Luxturna, Zolgensma), CRISPR (Casgevy). Diagnosis itself is therapeutic: ending the diagnostic odyssey.

Diagnosis is treatment's prerequisite

You cannot treat what you cannot name: genomic diagnosis unlocks everything downstream.

Key points

  • Single-gene (~7,000 rare), chromosomal (de novo aneuploidies), multifactorial (common diseases)
  • Rare diseases collectively affect ~1 in 17
  • Chromosomal usually de novo; Mendelian follow pedigree risks
  • Therapies: symptomatic, modulators, gene therapy, CRISPR

Common misconceptions

✗ Myth: Genetic disorders are untreatable.

✓ Truth: CFTR modulators, enzyme replacement, gene therapies, and even dietary (PKU) treatments prove otherwise.

✗ Myth: If it's genetic, family members will all have it.

✓ Truth: Recessive carriers are healthy; de novo cases don't affect siblings; penetrance varies.

Practice questions

Q1. Which class dominates human mortality?
  1. Single-gene
  2. Chromosomal
  3. Multifactorial (heart disease, diabetes, cancer)
  4. Mitochondrial
Answer: C.

Common multifactorial diseases cause most deaths, though each has genetic components.

Q2. Most chromosomal disorders are
  1. Inherited from parents
  2. De novo with low recurrence risk
  3. Contagious
  4. Preventable by diet
Answer: B.

Nondisjunction usually occurs sporadically: recurrence ~1%.

Q3. Trikafta treats cystic fibrosis by
  1. Gene editing
  2. Modulating mutant CFTR protein function
  3. Lung transplant
  4. Antibiotics only
Answer: B.

Small-molecule correctors/potentiators restore CFTR activity.

Click a question to reveal the answer and explanation.

Frequently asked questions

What is the diagnostic odyssey?

Years of inconclusive tests rare-disease patients endure; exome sequencing now ends many odysseys.

How do CFTR modulators work?

Small molecules (ivacaftor/lumacaftor/tezacaftor/elexacaftor) correct folding/gating of mutant CFTR: function restored pharmacologically.

Why screen newborns?

Conditions like PKU are treatable only if caught before damage: screening enables pre-symptomatic intervention.